NEW YORK, May 10, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0490908/KOL-insights-and-unmet-needs-in-Ulcerative-Colitis-and-Crohns-Disease.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Introductory offer: buy 2 Sociable Pharma reports get a third free. Introductory offer available until the end of May 2011.
Purchase Sociable Pharma's two reports on KOL insights and unmet needs in Ulcerative Colitis and Crohn's Disease and get Sociable Pharma view on future opportunities and scenarios free.
--Below are summaries of each report.
- Ulcerative Colitis: KOL insights on treatment practices and unmet needs
The use of biologics is still in its formative stages in the treatment of ulcerative colitis but adoption has already been significant and is set to expand considerably in the short- and medium-term. Sociable Pharma conducted in-depth primary research in the US and Europe with key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.
HIGHLIGHTS
Identifies the latest treatment trends in Ulcerative Colitis, including the role of biologics in steroid-refractory patients and acute/severe settings
Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines
Analyzes current treatment practices covering five major drug classes: aminosalicylates (5-ASAs), corticosteroids, immunomodulators, anti-TNF therapies, calcineurin inhibitors
Highlights opinion hotspots where treatment approaches differ between physicians and also between the US and Europe, such as the use of once daily oral dosing formulations for 5-ASAs
Assesses the impact of the 2011 SUCCESS trial
Identifies the most significant unmet needs, based on the treatment challenges facing physicians. Examples include adherence to 5-ASA regimens and managing long-term immunosuppression.
- Crohn's disease: KOL insights on treatment practices and unmet needs
Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.
HIGHLIGHTS
Identifies the latest treatment trends in Crohn's disease, including the growing importance of "top-down" treatment strategies for moderate-to-severe Crohn's disease
Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines
Analyzes current treatment practices covering seven major drug classes: aminosalicylates (5-ASAs), corticosteroids, immunomodulators, anti-TNF therapies, antibiotics, probiotics and nutritional therapy
Highlights opinion hotspots where treatment approaches differ between physicians and also between the US and Europe, such as the emerging treatment objective of complete mucosal healing
Assesses the impact of the SONIC trial
- Crohn's disease: future treatment scenarios and opportunities
Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.
HIGHLIGHTS
Identifies the latest treatment trends in Crohn's disease, including the growing importance of "top-down" treatment strategies for moderate-to-severe Crohn's disease
Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines
Identifies commercial opportunities in Crohn's disease treatment including:
1. Targeting patients naïve to anti-TNF therapies with novel oral inhibitors
2. Combination therapies with helminth in mild-to-moderate disease
3. Improved localized release of corticosteroids to reduce systemic side effects
Assesses future scenarios for Crohn's disease therapies, including:
1. Migration of anti-TNF therapies to new treatment settings
2. Impact of tailored induction and maintenance regimens
3. Future use of antibiotics, probiotics and helminth in mild-to-moderate disease
To order this report:
Pathology Industry:
Pathology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
http://www.reportlinker.com/p0490908/KOL-insights-and-unmet-needs-in-Ulcerative-Colitis-and-Crohns-Disease.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Advertisement
Introductory offer: buy 2 Sociable Pharma reports get a third free. Introductory offer available until the end of May 2011.
Purchase Sociable Pharma's two reports on KOL insights and unmet needs in Ulcerative Colitis and Crohn's Disease and get Sociable Pharma view on future opportunities and scenarios free.
--Below are summaries of each report.
- Ulcerative Colitis: KOL insights on treatment practices and unmet needs
The use of biologics is still in its formative stages in the treatment of ulcerative colitis but adoption has already been significant and is set to expand considerably in the short- and medium-term. Sociable Pharma conducted in-depth primary research in the US and Europe with key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.
HIGHLIGHTS
Identifies the latest treatment trends in Ulcerative Colitis, including the role of biologics in steroid-refractory patients and acute/severe settings
Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines
Analyzes current treatment practices covering five major drug classes: aminosalicylates (5-ASAs), corticosteroids, immunomodulators, anti-TNF therapies, calcineurin inhibitors
Highlights opinion hotspots where treatment approaches differ between physicians and also between the US and Europe, such as the use of once daily oral dosing formulations for 5-ASAs
Assesses the impact of the 2011 SUCCESS trial
Identifies the most significant unmet needs, based on the treatment challenges facing physicians. Examples include adherence to 5-ASA regimens and managing long-term immunosuppression.
- Crohn's disease: KOL insights on treatment practices and unmet needs
Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.
HIGHLIGHTS
Identifies the latest treatment trends in Crohn's disease, including the growing importance of "top-down" treatment strategies for moderate-to-severe Crohn's disease
Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines
Analyzes current treatment practices covering seven major drug classes: aminosalicylates (5-ASAs), corticosteroids, immunomodulators, anti-TNF therapies, antibiotics, probiotics and nutritional therapy
Highlights opinion hotspots where treatment approaches differ between physicians and also between the US and Europe, such as the emerging treatment objective of complete mucosal healing
Assesses the impact of the SONIC trial
- Crohn's disease: future treatment scenarios and opportunities
Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.
HIGHLIGHTS
Identifies the latest treatment trends in Crohn's disease, including the growing importance of "top-down" treatment strategies for moderate-to-severe Crohn's disease
Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines
Identifies commercial opportunities in Crohn's disease treatment including:
1. Targeting patients naïve to anti-TNF therapies with novel oral inhibitors
2. Combination therapies with helminth in mild-to-moderate disease
3. Improved localized release of corticosteroids to reduce systemic side effects
Assesses future scenarios for Crohn's disease therapies, including:
1. Migration of anti-TNF therapies to new treatment settings
2. Impact of tailored induction and maintenance regimens
3. Future use of antibiotics, probiotics and helminth in mild-to-moderate disease
To order this report:
Pathology Industry:
Pathology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
